CLINICAL TRIAL / NCT05682170
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
- Interventional
- Recruiting
- NCT05682170
Contact Information
A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor ZN-c3 in Subjects With Acute Myeloid Leukemia
A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia (AML).